Using blood tests to monitor ovarian cancer recurrence
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at whether changes in immune system markers in the blood can help detect if ovarian cancer comes back after treatment. It tests standard chemotherapy and surgery, with the goal of improving how doctors monitor the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with advanced-stage (III or IV) ovarian, fallopian tube, or primary peritoneal cancer.
- You have not received chemotherapy or other cancer treatment before surgery.
- You are scheduled to have initial surgery to remove as much tumor as possible, followed by 6–8 cycles of chemotherapy with carboplatin plus paclitaxel or docetaxel.
- You have not had your spleen removed.
- You have not received any vaccines in the past 2 months, and you have not taken antibiotics or had a blood transfusion in the past 2 weeks.
- You do not have a blood clotting disorder, HIV, active tuberculosis, or other serious infections.
- You have not taken immunosuppressive drugs in the past 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune-related markers in people with ovarian cancer to see if they can help predict prognosis (how the cancer may behave). If you qualify, your doctors may use your immune test results alongside other standard treatments like surgery, chemotherapy, and/or immunotherapy.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
This study looks at how the immune system works in people with epithelial ovarian cancer. It aims to understand the immune landscape around the tumor, which could lead to better treatments in the future.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This study uses whole-body scans to look at how active tumors are in women with suspected ovarian cancer. The goal is to see if these scans can predict how well treatment will work, which may help personalize care.
This study is testing whether a simple blood test can predict the risk of ovarian cancer coming back after treatment. It might help doctors decide who needs more aggressive therapy.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.